MM-151 (Not yet branded)

Description

MM-151 is a multi-specific antibody therapeutic that targets the epidermal growth factor receptor (EGFR) pathway in advanced solid tumors, including colorectal cancer. This compound represents a novel approach to EGFR inhibition by simultaneously binding to multiple epitopes on the EGFR protein. MM-151 has been evaluated in early-phase clinical trials for patients with treatment-resistant advanced solid malignancies, including those with colorectal cancer who have failed standard therapeutic approaches.

Mechanism of Action

MM-151 functions as a multi-specific antibody that binds to distinct epitopes on the EGFR protein, preventing receptor activation and subsequent downstream signaling cascades that promote tumor cell proliferation and survival. By targeting multiple binding sites simultaneously, this approach aims to overcome resistance mechanisms that commonly develop with single-epitope EGFR inhibitors like cetuximab or panitumumab.

Molecular Targets

Side Effects

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials